Why Was Levothyroxine Taken Off the Market?

Levothyroxine was never universally pulled from pharmacy shelves. What actually happened, repeatedly and in several countries, is that specific formulations and brands were suspended, recalled, or forced into reformulation because of potency and stability problems. The confusion is understandable: levothyroxine is one of the most prescribed medications in the world, and when regulators in the UK, France, New Zealand, and Denmark took action against individual products, the disruption was enormous. The story behind those actions reveals just how difficult this particular drug is to manufacture, store, and switch between brands.

What Actually Happened in the UK

In February 2012, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) suspended the license for Teva’s levothyroxine 100-microgram tablets. The reason was straightforward: prescribers and patients were reporting reduced effectiveness when they switched from other levothyroxine products to the Teva version. People whose thyroid levels had been stable for years were suddenly experiencing symptoms of underactive thyroid again after their pharmacy dispensed a different brand.

The suspension lasted more than four years. Teva eventually reformulated its tablets, making them lactose-free and changing the manufacturing process. The MHRA lifted the suspension in October 2016, but only after the company addressed the problems that had caused the potency shortfall in the first place.¹

The French Levothyrox Crisis

The most dramatic episode occurred in France in 2017. Merck reformulated its Levothyrox product (sold as Euthyrox in other European countries) to comply with tighter potency specifications. The active ingredient stayed the same. The dose stayed the same. What changed were minor elements of the formulation, mainly the inactive ingredients. On paper, this should have been unremarkable. In reality, it triggered one of the largest patient-reported adverse event crises in recent French pharmaceutical history.

By 2018, more than 17,000 reports of adverse events had been filed.¹ An analysis of patient notifications found that people reporting problems with the new Levothyrox formula described an average of about five symptoms per report, compared to roughly three for other drugs. Many of those symptoms were unrelated to thyroid disease or its treatment, spanning an unusually wide range of organ systems.²

The European Medicines Agency reviewed the situation and concluded that both the old and new formulations were bioequivalent, meaning they delivered the same amount of active drug into the bloodstream. The agency suggested that intense media coverage and heightened surveillance had amplified adverse event reporting.³ That explanation infuriated patients who felt their symptoms were real and were being dismissed. The episode became a case study in how reformulations of sensitive drugs intersect with public trust, media dynamics, and the limits of bioequivalence testing.⁴

France was not the first country to experience this pattern. New Zealand and Denmark had gone through similar upheavals roughly a decade earlier when their versions of Eltroxin (another levothyroxine brand) were reformulated, again with bioequivalent results on paper but widespread patient complaints in practice.¹

Why Small Formulation Changes Cause Big Problems

Levothyroxine is classified as a narrow therapeutic index drug by the FDA, Health Canada, and several European regulatory agencies.⁵ That classification matters because it means the gap between a dose that works and a dose that causes problems is unusually small. A tiny shift in how much active drug your body absorbs can push you from well-controlled to either overmedicated or undermedicated.

Even small differences between levothyroxine formulations can cause meaningful changes in thyroid-stimulating hormone levels. This is a particular concern in elderly patients, pregnant women, and children, whose thyroid regulation is already more delicate.¹ When a pharmacy substitutes one brand for another, the patient may be getting a product that passed bioequivalence testing but still delivers a slightly different amount of hormone. For most drugs, that difference would not matter. For levothyroxine, it can mean the difference between feeling fine and feeling awful.

Because of this sensitivity, regulators have tightened the bioequivalence standards for levothyroxine. Most drugs are considered interchangeable if their pharmacokinetic parameters fall within 80 to 125 percent of the reference product. For narrow therapeutic index drugs like levothyroxine, that window is squeezed to 90 to 111 percent.⁵ Those tighter margins explain why regulators forced reformulations in the first place: older products that had been on the market for decades did not always meet the new, stricter requirements.

A Drug That Degrades Easily

Part of the reason levothyroxine has caused so many regulatory headaches is that the molecule itself is chemically fragile. It breaks down when exposed to light and moisture,⁶ and the mechanism of degradation is now well understood. In solid form, levothyroxine sodium exists as a crystal that holds water molecules in its structure. When humidity drops too low, that water leaves the crystal, opening up channels through which oxygen can reach the drug and degrade it.⁷

Lab experiments have confirmed this pattern clearly. When levothyroxine sodium was stored in dry conditions with oxygen present, it degraded significantly over about a month. Remove the oxygen, and the dehydrated samples stayed stable. Keep the samples properly hydrated, and they also stayed stable regardless of whether oxygen was present.⁸ So the drug needs either its water of hydration or an oxygen-free environment to maintain potency. This is an unusually demanding set of conditions for a pill that millions of people keep in bathroom cabinets, which are humid and warm, or in purses and pill organizers, which are dry and exposed to air.

This instability explains why the potency of a levothyroxine tablet can drift during its shelf life. A product that leaves the factory at 100 percent potency might drop below acceptable limits before its expiration date, depending on how it was packaged and stored. That drift was the underlying problem that prompted regulators to tighten standards.

Tighter Potency Standards and Their Ripple Effects

Before 2009, the acceptable potency range for levothyroxine tablets in the United States was wider than it is today. The FDA and the US Pharmacopeia updated the specifications, requiring that tablets maintain between 95 and 105 percent of their labeled dose throughout their shelf life. Some other countries still accept a wider window; the British Pharmacopoeia, for example, allows 90 to 110 percent.⁵

These tighter rules were genuinely needed. A tablet at 90 percent potency and one at 110 percent deliver meaningfully different amounts of hormone to a patient who depends on a precise dose. But the new standards forced manufacturers to reformulate products that had been on the market for years, sometimes decades. Those reformulations changed inactive ingredients (binders, fillers, coatings) that influence how the tablet dissolves and how the drug is absorbed. And as the French experience demonstrated, even changes to inactive ingredients can provoke real clinical disruption in a drug this sensitive.

The Compounding Problem

While brand and generic tablets go through rigorous testing, compounded levothyroxine, the kind made by specialty pharmacies for patients who need customized doses or cannot tolerate certain excipients, has a consistency problem that is far worse. A study of compounded oral liquid levothyroxine products found that potency varied wildly. Individual product assays showed a range from 77 to 113 percent of the labeled strength on day three, but by day 34 the range had deteriorated to 30 to 97 percent. When patients ordered refills from the same compounding pharmacy, the potency difference between the original batch and the refill varied by as much as 58 percent.⁹

For a drug where a five or ten percent swing in absorption can push you out of your therapeutic range, a 58 percent batch-to-batch difference is extreme. Compounded levothyroxine fills an important niche for patients with specific needs, but these numbers illustrate why endocrinologists generally prefer commercially manufactured tablets when possible, and why patients using compounded preparations need more frequent blood monitoring.

Food, Supplements, and Absorption Interference

The challenges do not end once you have a consistent tablet. Levothyroxine’s absorption is also influenced by what you eat and what other pills you take around the same time. A systematic review found that coffee, soy products, fiber, calcium supplements, iron supplements, and enteral nutrition all reduced levothyroxine absorption.¹⁰ The calcium interaction has been studied closely: in one trial, taking calcium carbonate alongside levothyroxine pushed thyroid-stimulating hormone levels up significantly, with a fifth of patients drifting above the normal range. The mechanism is chemical, as calcium physically adsorbs levothyroxine at acidic pH, essentially trapping it in the stomach before it can be absorbed.¹¹

This is relevant to the broader story because absorption interference creates the same downstream problem as a potency shortfall: your body receives less active hormone than intended. If you are already taking a formulation that sits near the low end of potency tolerance, and you wash it down with a calcium supplement or a cup of coffee, you can end up functionally undermedicated even though the prescription is technically correct. The standard advice to take levothyroxine on an empty stomach, at least 30 to 60 minutes before food, and at least four hours away from calcium or iron, exists precisely because the margin for error is so thin.

Where the Raw Ingredients Come From

An underappreciated piece of the levothyroxine supply puzzle is the global sourcing of its active pharmaceutical ingredient. An analysis of pharmaceutical import data found that nearly 97 percent of levothyroxine’s imported active ingredient cost in the US came from Europe.¹² That heavy dependence on a single region means that trade disruptions, tariffs, or supply chain problems in Europe could directly affect levothyroxine availability and price in the US. Under a Europe-only tariff scenario, the estimated price increase for levothyroxine was about four percent, relatively small in absolute terms but meaningful for a medication taken daily and indefinitely by millions of people.

This concentration of supply also raises quality-control questions. When most of the world’s active ingredient for a single drug flows through a handful of European manufacturers, any disruption at a single facility can cascade into shortages. Patients who have been told never to switch brands suddenly find their brand unavailable, and they are forced into exactly the kind of substitution that has historically caused problems.

When Levothyroxine Alone Is Not Enough

Separate from the formulation controversies, a growing number of patients report persistent symptoms despite taking levothyroxine and having blood tests that look normal. The most common complaints are fatigue and low energy, reported by roughly 80 to 90 percent of patients with persistent symptoms, along with difficulties with weight management, memory, and mood.¹³

Levothyroxine provides the body with T4, one of the two main thyroid hormones. Your body is supposed to convert T4 into T3, the more biologically active form. But some patients appear not to convert T4 efficiently, and for these individuals, adding a small dose of T3 (liothyronine) has shown promise in case reports. In one small case series, patients who added liothyronine to their levothyroxine saw their total T3 levels rise and their symptom burden decrease.¹⁴

Longer-term data on combination therapy is more nuanced. A study following patients on combined T4/T3 treatment found that those who responded well achieved quality-of-life scores comparable to the general population, which was a substantial improvement over their scores on levothyroxine alone. However, both responders and non-responders still reported many hypothyroid symptoms, with scores comparable to untreated patients with overt hypothyroidism.¹⁵ Combination therapy has gained popularity, particularly in wealthier countries, but it remains controversial among endocrinologists and is not yet recommended as standard first-line treatment. For patients frustrated by persistent symptoms on levothyroxine, it represents one of the few alternatives being studied seriously.

How to Protect Yourself From Formulation Changes

If you take levothyroxine, the practical lessons from these episodes are worth knowing. Ask your pharmacy to dispense the same manufacturer’s product each time you refill. In many countries, pharmacies are allowed to substitute a generic from whichever manufacturer is cheapest that week, and for most drugs this does not matter. For levothyroxine, even switching between products that are technically bioequivalent can nudge your thyroid levels enough to cause symptoms.¹⁶

Store your tablets properly. The drug’s sensitivity to moisture and oxygen means that keeping it in a bathroom medicine cabinet, where heat and humidity fluctuate with showers, is not ideal. A cool, dry bedroom drawer is a better choice. If your tablets come in blister packaging rather than a bottle, that offers some additional protection against moisture exposure.

If you are forced to switch formulations due to a shortage or a pharmacy change, do not panic, but do get your blood tested about six weeks after the switch. That gives your body enough time to reach a new steady state on the slightly different product. Your doctor can adjust your dose based on the results. And if you take calcium, iron, or other supplements, keep them well separated from your morning levothyroxine dose. The interaction is real, reproducible, and entirely avoidable with timing alone.

1
PubMed Central. Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution
2
PubMed. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox amidst a drug media crisis: atypical profile as compared with other drugs
3
PubMed. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills
4
PubMed Central. Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?
5
PubMed Central. Levothyroxine Bioequivalence Study and Its Narrow Therapeutic Index: Comparative Bioavailability Results Between Two Formulations Available in Latin America
6
AAPS Open. Stability of levothyroxine tablets in blister packaging versus bottles and vials under simulated in-use conditions
7
PubMed. New Insights on Solid-State Changes in the Levothyroxine Sodium Pentahydrate during Dehydration and its Relationship to Chemical Instability
8
PubMed. Impact of hydration state and molecular oxygen on the chemical stability of levothyroxine sodium
9
PubMed Central. Stability and consistency of compounded oral liquid levothyroxine formulations
10
PubMed Central. Levothyroxine Interactions with Food and Dietary Supplements–A Systematic Review
11
PubMed. Effect of calcium carbonate on the absorption of levothyroxine
12
Health Affairs Scholar. Potential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs
13
PubMed Central. T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
14
Journal of Clinical and Translational Endocrinology: Case Reports. Combination therapy with levothyroxine and liothyronine in hypothyroid patients with persistent symptoms: A case series
15
European Thyroid Journal. Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms
16
PubMed. Importance of right communication with healthcare providers and patients about the new levothyroxine formulation: an expert opinion from Asia Pacific Thyroid Advisory Board